Drug Profile
Garetosmab - Regeneron Pharmaceuticals
Alternative Names: R2477; REGN-2477Latest Information Update: 05 Apr 2024
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals
- Class Antibodies; Monoclonal antibodies; Osteoporosis therapies
- Mechanism of Action Activin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Fibrodysplasia ossificans progressiva
- Phase II Obesity
- Preclinical Osteoporosis
- No development reported Musculoskeletal disorders
Most Recent Events
- 13 Mar 2024 Phase-II clinical trials in Obesity (Combination therapy) in USA (IV) (NCT06299098)
- 09 Aug 2023 3811114-No updates, data from post-hoc analysis, hence not covered
- 15 Jun 2023 Pharmacokinetics and immunogenicity data from the phase II LUMINA-1 in Fibrodysplasia ossificans progressiva presented at the 105th Annual Meeting of the Endocrine Society (ENDO-2023)